eERA stands for 'extended' Environmental Risk Assessment. It provides a mechanism for ongoing environmental review post-marketing authorisation (MA) approval for new APIs authorised since 1st December 2006, a framework considering the total risk of all medicinal products containing the same API and a commitment from industry to follow up on new scientific information and identified risks in a responsible fashion. If an environmental risk is identified after the MA, an extended ERA process can provide a way to follow up on any additional studies agreed with the regulator in order to investigate, refine and resolve risks identified by the original ERA, and to evaluate the ERA, for example periodically based on new data available for the total use of the active pharmaceutical ingredient (API) and for its environmental concentrations and effects.